Departments of Urology, Epidemiology, Oncology, and Environmental Health Sciences, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.
The prostate has long been known to exhibit unique metabolite profiles. In the last decade, advances in nuclear magnetic resonance spectroscopy and mass spectrometry have been applied toward identifying metabolic alterations in prostate cancer that may provide clinically useful biomarkers. As with genomics and proteomics, advances in technology and bioinformatics have led to the application of metabolomic profiling to prostate cancer-the high throughput evaluation of a large complement of metabolites in the prostate and how they are altered by disease perturbations. Recently, high profile publications have drawn attention to the potential of metabolomic analysis to identify biomarkers for early detection or disease progression from readily accessible body fluids as well as tissue specimens from biopsy and surgery. This review will examine applications of metabolomics to prostate cancer and highlight clinical associations and potential challenges.
Written by:
Trock BJ. Are you the author?
Reference: Urol Oncol. 2011 Sep-Oct;29(5):572-81.
doi: 10.1016/j.urolonc.2011.08.002
PubMed Abstract
PMID: 21930089
UroToday.com Prostate Cancer Section
